v3.25.1

Equity Investments - Additional Information (Details) - USD ($) | Jan. 31, 2024 | Dec. 31, 2023
--- | --- | ---
Investment In Frontier Medicines [member] |  |
Disclosure of financial assets [line items] |  |
Equity investment | $ 40,000,000 |
Non-listed company [member] |  |
Disclosure of financial assets [line items] |  |
Equity investment |  | $ 15,000,000

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfFinancialAssetsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of instruments held by the entity that provide evidence of a residual interest in the assets of another entity after deducting all of its liabilities. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 55 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_EquityInstrumentsHeld
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | ifrs-full_ClassesOfFinancialAssetsAxis=glpg_InvestmentInFrontierMedicinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfFinancialAssetsAxis=glpg_NonListedCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |